Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BET Bromodomain Inhibition as a Therapeutic Strategy in Ovarian Cancer by Downregulating FoxM1

10 Dec 2015

Abstract excerpt

Ovarian cancer is responsible for the highest mortality among all gynecologic malignancies, and novel therapies are urgently needed to improve patient outcome. Here we performed an integrative genomic analysis and identified the bromodomain and extraterminal domain (BET) protein BRD4 as a potential therapeutic target in ovarian cancer. Suppression of BRD4 using small-molecule BET inhibitors JQ1 and I-BET151, or...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chromatin Remodeling and Cancer
Share to Multiple Myeloma Research and Treatments
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26877780
DOI: 10.7150/thno.13178

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BET Bromodomain Inhibition as a Therapeutic Strategy in Ovarian Cancer by Downregulating FoxM1PMID 26877780Read ↗

Targeting BET Bromodomains for Cancer TreatmentSemantic proximity Read ↗

Targeting BET Bromodomains in CancerSemantic proximity Read ↗

Unraveling the Role of Bromodomain and Extra-Terminal Proteins in Human Uterine LeiomyosarcomaSemantic proximity Read ↗

BRD4 and Cancer: going beyond transcriptional regulationSemantic proximity Read ↗

Bromodomain and extra-terminal (BET) inhibitors in treating myeloid neoplasmsSemantic proximity Read ↗

The BET bromodomain inhibitor JQ1 suppresses growth of pancreatic ductal adenocarcinoma in patient-derived xenograft modelsSemantic proximity Read ↗

Nonselective inhibition of the epigenetic transcriptional regulator BET induces marked lymphoid and hematopoietic toxicity in miceSemantic proximity Read ↗

BRDT promotes ovarian cancer cell growthSemantic proximity Read ↗

Bromodomain inhibitor treatment leads to overexpression of multiple kinases in cancer cellsSemantic proximity Read ↗

Inhibition of Bromodomain Proteins for the Treatment of Human Diffuse Large B-cell LymphomaSemantic proximity Read ↗

<i>In Silico</i> Analysis Guides Selection of BET Inhibitors for Triple-Negative Breast Cancer TreatmentSemantic proximity Read ↗

Domain-selective targeting of BET proteins in cancer and immunological diseasesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.